Physician profile
Jonathan Mowrey
NPI 1659878874
$690.60
in general payments reported to CMS, 2019-2025
13 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.48 · 2022: $124 · 2023: $191 · 2024: $185 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.98 | 2022 | |
| Mozarc Medical US LLC | $103.55 | 2023-2025 | Chameleon |
| Novo Nordisk INC | $74.25 | 2024-2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $72.39 | 2024-2025 | Jynarque |
| Amgen INC. | $45.55 | 2025 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.52 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $27.31 | 2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $20.35 | 2024 | |
| Akebia Therapeutics INC | $19.27 | 2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $15.98 | 2025 | Velphoro |
| Glaxosmithkline, LLC. | $14.98 | 2025 | Benlysta |
| Lilly USA, LLC | $14.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mowrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.